Please assess the completion status of the following clinical trial:

Trial Title: A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Each participant must meet all of the following inclusion criteria to be enrolled in the study:~1. Male or female participants 18 years or older, with relapsed or refractory classical Hodgkin lymphoma (HL), who have previously received at least 1 prior systemic chemotherapeutic regimen~2. Not suitable for stem cell transplantation (SCT) or multiagent chemotherapy, according to 1 of the following criteria:~   * Disease progression within 90 days of the earliest date of complete remission (CR) or complete remission unconfirmed (CRu) after the end of treatment with multiagent chemotherapeutic regimens and/or radiotherapy~  * Progressive disease during frontline multiagent chemotherapy~  * Disease relapse after treatment with at least 2 chemotherapeutic regimens, including any salvage treatments~3. Bidimensional measurable disease~4. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1~5. Female participants who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception at the same time, or agree to practice true abstinence.~6. Male participants who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence.~7. Clinical laboratory values as specified in the study protocol.~Exclusion Criteria:~Participants who meet any of the following exclusion criteria are not to be enrolled in the study:~1. Previous treatment with brentuximab vedotin~2. Previously received an autologous stem cell transplantation (ASCT) or alloSCT~3. Known cerebral/meningeal disease, including signs or symptoms suggestive of progressive multifocal leukoencephalopathy (PML), or any history of PML.~4. Female participants who are lactating and breastfeeding or pregnant.~5. Known human immunodeficiency virus (HIV).~6. Known hepatitis B surface antigen positive, or known or suspected active hepatitis C infection.~7. Grade 2 or higher peripheral neuropathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab Vedotin 1.8 mg/kg (Type: EXPERIMENTAL): Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose could be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.

Based on this trial design, predict the completion outcome and termination type (if applicable).